International Clinical Trial: A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, Radiological and Clinical Effects of Subcutaneous Ublituximab in Participants With Relapsing Multiple Sclerosis

Geneva, Oct. 21 -- International Clinical Trials Registry received information related to the study (CTIS2025-521127-73-00) titled 'A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, Radiological and Clinical Effects of Subcutaneous Ublituximab in Participants With Relapsing Multiple Sclerosis' on April 25.

Study Type: Interventional clinical trial of medicinal product

Study Design: Controlled: no Randomised: no Open: no Single blind: no Double blind: no Parallel group: no Cross over: no Other: no If controlled, specify comparator, Other Medicinial Product: no Placebo: no Number of treatment arms in the trial:

Primary Sponsor: Tg Therapeutics Inc.

Condition: Relapsing forms of Multiple Sclerosis MedDRA version: 27....